Generic Pharmaceutical Manufacturer
Issues related to FDA rule on drug labeling; issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94). P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013. H.R. 2725- FDA Safety Over Sequestration Act
PHA - Pharmacy HCR - Health Issues BUD - Budget/Appropriations
135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
BROWN RUDNICK LLP
601 13th Street, NW, 6th Floor, Washington, DC, 20005, US
CHRISTOPHER BOWLIN HENRY W MENN LISA LAYMAN CHRISTOPHER BOWLIN HENRY W MENN LISA LAYMAN CHRISTOPHER BOWLIN (Dep Asst Secr for Congr & Intgv Affairs) LISA LAYMAN (SPA, Sen Stabenow(05-07)) HENRY W MENN (Min SD & Counsel, Cmte on Vet Affairs (04))
Dep Asst Secr for Congr & Intgv Affairs SPA, Sen Stabenow(05-07) Min SD & Counsel, Cmte on Vet Affairs (04)